Monday, May 10, 2010

Oral Therapies for MS

The Findings:
TRANSFORMS STUDY
Oral fingolimid vs. interferon beta 1A : at one year ,no difference in disability at one year. Fingolimid 0.5 mg/d 52% reduction in relapse rate ; 1.25 mg/d 38% reduction
FREEDOMS STUDY
Fingolimid superior to placebo re: new lesions
CLARITY TRIAL
Cladribine vs placebo, significant reduction in brain lesions on MRI

No comments:

Post a Comment